image

Investors

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Archived Events
RBC’s Antibody-Drug Conjugate Day: Virtual Symposium Exploring Future of ADCs Across Tumor Types And Approaches
October 4, 2023
Click here for webcast
Baird Global Healthcare Conference
September 12, 2023 at 12:45 PM EDT
View Webcast
Wells Fargo Healthcare Conference
September 7, 2023 at 3:00 PM EDT
View Webcast
RBC Capital Markets 2023 Global Healthcare Conference
May 17, 2023 at 4:35 PM EDT
View Webcast
22nd Annual Needham Virtual Healthcare
April 20, 2023 at 3:00 PM EDT
View Webcast
Oppenheimer 33rd Annual Healthcare Conference
March 14, 2023 from 10:40 AM to 11:10 AM EDT
View Webcast
Corporate Presentations
Scientific Presentation
Print Page
Email Alerts
RSS Feeds
Contact IR